[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
作者信息
Grülllich C
机构信息
Uniklinik-Dresden, Haus 27, Fetscherstr. 74, 01307, Dresden, Deutschland.
出版信息
Urologe A. 2020 Apr;59(4):478-479. doi: 10.1007/s00120-020-01160-6.
PMID:32103289
Abstract
摘要
相似文献
1
[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].厄达替尼用于铂类化疗失败后的FGFR突变型尿路上皮癌患者的高缓解率
Urologe A. 2020 Apr;59(4):478-479. doi: 10.1007/s00120-020-01160-6.
2
Erdafitinib for advanced urothelial carcinoma.厄达替尼用于晚期尿路上皮癌。
Lancet Oncol. 2019 Sep;20(9):e469. doi: 10.1016/S1470-2045(19)30522-4. Epub 2019 Aug 1.
3
Erdafitinib: First Global Approval.厄达替尼：全球首次批准。
Drugs. 2019 Jun;79(9):1017-1021. doi: 10.1007/s40265-019-01142-9.
4
Erdafitinib to treat urothelial carcinoma.厄达替尼用于治疗尿路上皮癌。
Drugs Today (Barc). 2019 Aug;55(8):495-501. doi: 10.1358/dot.2019.55.8.3010573.
5
Erdafitinib (Balversa) for urothelial carcinoma.厄达替尼（Balversa）用于治疗尿路上皮癌。
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-e84. doi: 10.58347/tml.2024.1702g.
6
Fibroblast growth factor receptors across urothelial carcinoma landscape.成纤维细胞生长因子受体在尿路上皮癌中的研究进展。
Curr Opin Urol. 2020 Jul;30(4):557-565. doi: 10.1097/MOU.0000000000000782.
7
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.关于：厄达替尼或化疗用于晚期或转移性尿路上皮癌
Eur Urol. 2024 Jun;85(6):591-592. doi: 10.1016/j.eururo.2024.02.020. Epub 2024 Mar 26.
8
Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.在可能从厄达非尼治疗中获益的转移性或局部晚期、手术不可切除的尿路上皮癌患者中，使用基于RNA的检测方法鉴定成纤维细胞生长因子受体基因改变。
J Pathol Clin Res. 2020 Jul;6(3):207-214. doi: 10.1002/cjp2.163. Epub 2020 Apr 18.
9
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.三期 THOR 日本亚组分析：erdafitinib 治疗晚期或转移性尿路上皮癌和成纤维细胞生长因子受体改变。
Int J Clin Oncol. 2024 Oct;29(10):1516-1527. doi: 10.1007/s10147-024-02583-3. Epub 2024 Jul 17.
10
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.厄达替尼治疗局部晚期或转移性尿路上皮癌。
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
Zotero 插件